source
- Slate Medicines to merge with Fulcrum Therapeutics after Fulcrum drops sickle-cell drugSlate Medicines announced it will combine with Fulcrum Therapeutics in a reverse merger, giving the struggling biotech a new corporate home. Fulcrum had been developing pociredir, a therapy design…
- Saudi FDA launches program to accelerate rare-disease drug developmentThe Saudi Food and Drug Authority (SFDA) announced a new initiative called the New Accelerator Program for Drugs in Rare Diseases (NADR). The program is designed to speed up the development, evalu…